Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Quest Diagnostics; Rosetta Genomics; GeneNews

NEW YORK (GenomeWeb News) – Quest Diagnostics this week said that its Simplexa Flu A/B & RSV Direct test has received the CE Mark and has been launched in Europe. The molecular test, developed by the firm's Focus Diagnostics business, runs on the 3M Integrated Cycler. The test uses a proprietary technique to eliminate nucleic-acid sample extraction, leading to faster results reporting, said Quest.

Rosetta Genomics has raised $1.5 million of its planned $1.9 million target in a private placement, according to documents filed with the US Securities and Exchange Commission. Last month the firm said that it had reached definitive agreements to place the common stock and warrants with investors.

GeneNews this week said that its shareholders have approved the proposed consolidation of the firm's issued and outstanding shares on the basis of one post-consolidation common share for every six pre-consolidation common shares. The Canadian molecular diagnostics firm has not set a definitive date for the reverse split, but said that it would take place no later than Jan. 31, 2012.

"We believe that this proposed share consolidation will provide shareholders with the potential for a more attractive share price, reduced shareholder transaction costs, and improved trading liquidity as our partners prepare to launch ColonSentry in their respective markets," GeneNews President and COO Gailina Liew said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more